Medicare Extends Interim Coverage of Weight Loss Drugs, Suspends Pilot Program

Insurers had been scheduled to cover the GLP-1 medications, but pushed back against the plan.

Medicare and Medicaid Administrator Dr. Mehmet Oz speaks in the Oval Office in Washington on Nov. 6, 2025. Andrew Caballero-Reynolds/AFP via Getty Images

Medicare will keep covering popular glucagon-like peptide-1 drugs through the end of 2027, the Centers for Medicare and Medicaid Services (CMS) said on April 21.

The continuation of the bridge program will ensure that beneficiaries keep having access to the drugs, known as GLP-1s, officials said in a memorandum.